Related Experiment Video

Updated: Jun 19, 2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Antisense oligonucleotides as innovative therapeutic strategy in the treatment of high-grade gliomas

Gerardo Caruso1, Mariella Caffo, Giuseppe Raudino

  • 1Neurosurgical Clinic, Department of Neurosciences Psychiatry and Anaesthesiology, University of Messina School of Medicine, Messina, Italy. gcaruso@unime.it

Recent Patents on CNS Drug Discovery
|October 17, 2009
PubMed

Insights

Antisense oligonucleotides offer a targeted approach to combat high-grade gliomas by modulating specific gene expression. This review explores their mechanism and clinical potential in treating these aggressive brain tumors.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • High-grade gliomas have a poor prognosis despite extensive research.
  • Current therapies are limited by a lack of specificity against malignant cells.
  • The extracellular matrix and its proteins (tenascin, laminin, fibronectin) are crucial for glioma invasion and motility.

Purpose of the Study:

  • To review the mechanisms of action of antisense oligonucleotides.
  • To summarize preclinical and clinical studies of antisense oligonucleotide therapy for high-grade gliomas.
  • To report on patents related to this therapeutic strategy in gliomas.

Main Methods:

  • Review of existing literature on antisense oligonucleotide mechanisms.
  • Analysis of clinical and experimental studies in high-grade glioma treatment.
  • Compilation of patent information for antisense oligonucleotide therapies in cerebral gliomas.

Main Results:

  • Antisense oligonucleotides selectively inhibit gene expression by hybridizing with specific mRNA.
  • This targeted approach shows promise for modulating tumorigenesis-related genes.
  • Various studies and patents indicate the potential of this therapy in preclinical and clinical settings for gliomas.

Conclusions:

  • Antisense oligonucleotide therapy presents a promising strategy for targeted treatment of high-grade gliomas.
  • Its specificity offers potential for increased efficacy and reduced toxicity compared to conventional therapies.
  • Further research and clinical trials are warranted to fully realize the therapeutic potential of antisense oligonucleotides in neuro-oncology.

More Related Videos

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...